trivalent p2-vp8
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2020 (NCT04344054)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- RotavirusImmunity, active
Rotavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04344054 | Phase 2 | Sep 30, 2020 | Bill and Melinda Gates Foundation, Murdoch University, PATH, SK Bioscience Co., Ltd., University of Cincinnati |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Murdoch University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| PATH | Academic/Hospital | 1 | 1 | 1 | 2020 |
| SK Bioscience Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1